This session will focus on the difficulty of evaluating HCC patient scans after local intervention and how sponsors can overcome the complexities associated with imaging in HCC clinical trials.
- Highlight the challenges of the disease-free status of HCC and how to best identify recurrence after local interventional treatment and ablation.
- Provide examples of making the right call, whether an enhancement or irregularity
- Present the disease-inherent uncertainties that impact HCC clinical trial design
- Demonstrate how to plan for Blinded Independent Central Review to avoid pitfalls in your HCC study and protocol planning
Lencioni Riccardo, MD
Director, Cancer Imaging Program, Pisa University Hospital, Pisa, Italy
Professor Lencioni is one of the world’s foremost interventional oncology specialists, known especially for his highly influential work in liver cancer. He has been the principal investigator of several large, multicenter, randomized clinical trials investigating the use of image-guided interventions for the treatment of hepatocellular carcinoma and the potential synergies between loco-regional and systemic therapies.
Anja Urbank, R.T.
Medical Director, Medical & Scientific Services, Calyx
Anja is a certified radiology technician with over 20 years of experience managing the imaging components of global clinical trials, including the implementation of several oncology review criteria (e.g. RECIST, mRECIST, irRECIST, PCWG, Lugano) and indications.